[The therapeutic efficacy of interferon-alfa-2a (Roferon-A) in chronic hepatitis C].

Abstract

THE AIM OF THE STUDY:

Evaluation of 6-month treatment with roferon-A of patients with chronic hepatitis C (CHC) and comparison of the treatment regimens.

MATERIAL AND METHODS:

79 CHC patients received roferon-A for 3 months in a dose 6,000,000 IU 3 time a week. In case of the response to treatment was continued for the next 3 months (3,000,000 IU 3 times a week). Clinical-laboratory findings, results, of EIA and liver biopsy histology were examined.

RESULTS:

Primary remission was achieved in 71.8% of cases. 36.9% of patients developed recurrences including 14.1% recurrence arising in the course of therapy. Stable remission was obtained in 32.4% of patients. 28.2% patients were non-responders. Side effects were mild, discontinuation of the treatment was necessary only in 7% of cases.

CONCLUSION:

Roferon-A administration in a dose 6,000,000 IU for 24 weeks is optimal both as related to cost and efficacy of the treatment.

• Authors: V T Ivashkin, V V Gorbakov, B N Lytsar', A P Vasil'ev
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 69 Issue 8 Pg. 31-7 ( 1997) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Terapevticheskaia éffektivnost' interferona-al'fa-2a (roferona-A) pri khronicheskikh gepatitakh C.
• PMID: 9381387 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins

Topics

• Adolescent
• Adult
• Aged
• Analysis of Variance
• Antiviral Agents (adverse effects, therapeutic use)
• Chi-Square Distribution
• Chronic Disease
• Dose-Response Relationship, Drug
• Hepatitis C (diagnosis, therapy)
• Humans
• Interferon alpha-2
• Interferon-alpha (adverse effects, therapeutic use)
• Middle Aged
• Patient Selection
• Prognosis
• Recombinant Proteins
• Remission Induction
• Time Factors